Skip to main content

Acorda Therapeutics, Inc. (ACOR)

NASDAQ: ACOR · IEX Real-Time Price · USD
15.09
+0.10 (0.67%)
At close: Dec 29, 2023, 4:00 PM
15.50
+0.41 (2.72%)
After-hours: Dec 29, 2023, 7:56 PM EST

Acorda Therapeutics Revenue

Acorda Therapeutics had revenue of $111.12M in the twelve months ending September 30, 2023, down -10.43% year-over-year. Revenue in the quarter ending September 30, 2023 was $27.72M, a -17.30% decrease year-over-year. In the year 2022, Acorda Therapeutics had annual revenue of $118.57M, a decrease of -8.14%.

Revenue (ttm)
$111.12M
Revenue Growth
-10.43%
P/S Ratio
0.16
Revenue / Employee
$1,001,063
Employees
111
Market Cap
18.08M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2022118.57M-10.51M
-8.14%
Dec 31, 2021129.07M-23.90M
-15.62%
Dec 31, 2020152.97M-39.44M
-20.50%
Dec 31, 2019192.41M-279.03M
-59.19%
Dec 31, 2018471.43M-116.85M
-19.86%
Dec 31, 2017588.29M68.69M
13.22%
Dec 31, 2016519.60M26.94M
5.47%
Dec 31, 2015492.66M91.18M
22.71%
Dec 31, 2014401.48M65.05M
19.34%
Dec 31, 2013336.43M30.62M
10.01%
Dec 31, 2012305.81M13.58M
4.65%
Dec 31, 2011292.24M101.23M
53.00%
Dec 31, 2010191.01M136.33M
249.36%
Dec 31, 200954.67M6.85M
14.31%
Dec 31, 200847.83M8.34M
21.12%
Dec 31, 200739.49M12.13M
44.37%
Dec 31, 200627.35M22.21M
431.55%
Dec 31, 20055.15M9.08M
-230.69%
Dec 31, 2004-3.94M-4.41M
-931.35%
Jun 30, 2003473.59K342.00K
259.89%
Dec 31, 2002131.59K--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Pieris Pharmaceuticals 47.36M
DURECT 9.19M
NEXGEL 3.53M
Nutriband 2.09M
Fresh2 Group 1.63M
TFF Pharmaceuticals 932.32K
Revenue Rankings

ACOR News

More News